[Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Programmed death-1 (PD-1) and programmed death-1 ligand (PD-L1) inhibitors have revolutionized non-small cell lung cancer (NSCLC) treatment.
• PD-1/PD-L1 inhibitors appear less effective in NSCLC patients with epidermal growth factor receptor (EGFR) mutations.
• PD-L1 expression on tumor cells is linked to therapeutic response, but its correlation with EGFR mutation status is debated.

Purpose of the Study:

• To review and summarize current research on the impact of EGFR mutations on PD-L1 expression in NSCLC.
• To clarify the relationship between EGFR mutation status and PD-L1 expression levels.
• To provide insights for improving basic research and clinical treatment strategies for NSCLC.

Main Methods:

• Literature review of relevant studies.
• Synthesis of findings regarding PD-1/PD-L1 inhibitors, NSCLC, EGFR mutations, and PD-L1 expression.
• Analysis of existing data to identify trends and discrepancies.

Main Results:

• Evidence suggests a complex interaction between EGFR mutations and PD-L1 expression, influencing immunotherapy response.
• Inconsistent findings exist regarding whether EGFR mutations upregulate or downregulate PD-L1 expression.
• Understanding this relationship is crucial for predicting patient response to PD-1/PD-L1 inhibitors.

Conclusions:

• Further research is needed to fully elucidate the role of EGFR mutations in modulating PD-L1 expression in NSCLC.
• Clarifying the EGFR-PD-L1 axis can help personalize NSCLC treatment strategies, optimizing the use of immunotherapies.
• This review aims to contribute to a better understanding for both basic science and clinical application.